Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral Leishmaniasis: A Randomized, Open-Label Study

PLoS Neglected Tropical Diseases

Volumn 8, Issue 9, 2014, Pages

  Sundar, Shyam ^a   Pandey, Krishna ^b   Thakur, Chandreshwar Prasad ^c   Jha, Tara Kant ^d   Das, Vidya Nand Ravi ^b   Verma, Neena ^b   Lal, Chandra Shekhar ^b   Verma, Deepak ^e   Alam, Shahnawaz ^e   Das, Pradeep ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^c Balaji Utthan Sansthan   (India)

^d Kalazar Research Centre Brahmpura   (India)

^e Kala azar Research Center   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; LIPID EMULSION; LIPOSOME; AMPHOTERICIN B LIPID COMPLEX; ANTIPROTOZOAL AGENT; EMULSION;

ADOLESCENT; ADULT; AGED; AMASTIGOTE; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CHILD; CHILL; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; FEVER; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SINGLE DRUG DOSE; VISCERAL LEISHMANIASIS; VOMITING; ANIMAL; CONTROLLED STUDY; EMULSION; INDIA; LEISHMANIASIS, VISCERAL; MIDDLE AGED; SHEEP; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; EMULSIONS; FEMALE; FEVER; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; SHEEP; YOUNG ADULT;

EID: 84907573404     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003169     Document Type: Article

References (29)

1. Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, et al. (2010) Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 83: 357–364.
2. Leishmaniasis: Epidemiology and access to medicines. Available: http://www.who.int/leishmaniasis/resources/Leishmaniasis_worldwide_epidemiological_and_drug_access_update.pdf. Accessed 30 July 2013.
3. Perry D, Dixon K, Garlapati R, Gendernalik A, Poche D, et al. (2013) Visceral leishmaniasis prevalence and associated risk factors in the saran district of Bihar, India, from 2009 to July of 2011. Am J Trop Med Hyg 88: 778–784.
4. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, et al. (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10: 184–194.
5. Sundar S, (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849–854.
6. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, et al. (2007) Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 196: 591–598.
7. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, et al. (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341: 1795–1800.
8. Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, et al. (2011) Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg 85: 66–69.
9. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739–1746.
10. Sundar S, Olliaro PL, (2007) Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag 3: 733–740.
11. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, et al. (2012) Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543–550.
12. Sinha PK, Jha TK, Thakur CP, Nath D, Mukherjee S, et al. (2011) Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. J Trop Med 2011: 645203.
13. Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, et al. (2009) Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 200: 357–360.
14. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW, (2001) Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323: 419–422.
15. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, et al. (2003) Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37: 800–804.
16. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, et al. (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17: 493–510.
17. Sundar S, Singh A, Agarwal D, Rai M, Agrawal N, et al. (2009) Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am J Trop Med Hyg 80: 700–703.
18. Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, et al. (2008) Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop Med Int Health 13: 1208–1212.
19. Stauch A, Duerr HP, Dujardin JC, Vanaerschot M, Sundar S, et al. (2012) Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India. PLoS Negl Trop Dis 6: e1973.
20. den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M, (2009) Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 14: 395–410.
21. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, et al. (2004) Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377–383.
22. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873–882.
23. Boelaert M, Meheus F, Robays J, Lutumba P, (2010) Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis. Ann Trop Med Parasitol 104: 535–542.
24. Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, et al. (2008) Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res 128: 38–44.
25. Das VN, Ranjan A, Pandey K, Singh D, Verma N, et al. (2012) Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India. Am J Trop Med Hyg 86: 959–961.
26. Burza S, Sinha PK, Mahajan R, Sanz MG, Lima MA, et al. (2014) Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis 8: e2611.
27. World Health Organization Control of the leishmaniases: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO technical report series; no. 949. Geneva: WHO.
28. Mathur P, Samantaray JC, Vajpayee M, Samanta P, (2006) Visceral leishmaniasis/human immunodeficiency virus co-infection in India: The focus of two epidemics. J Med Microbiol 55: 919–922.
29. Cota GF, de Sousa MR, Fereguetti TO, Rabello A, (2013) Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: A systematic review with indirect comparison. PLoS Negl Trop Dis 7: e2195.